A RETROSPECTIVE CLINICAL STUDY EVALUATING THE EARLY RESPONSE TO ANTIDEPRESSANT MEDICATION IN ADULT SUBJECTS WITH MAJOR DEPRESSION

Abstract

Background: It has been demonstrated that evaluating the early response to antidepressant medication after two to four
weeks may reliably predict remission by eight to twelve weeks. Most of the earlier research on the literature assessed
randomised controlled trials.
Aim: The purpose of this study was to assess the early effects of antidepressant medication on adult participants suffering
from severe depressive disorder.
Methods: At different time periods, the study evaluated baseline reductions in Patient Health Questionnaire 9 scores.
Clinical and demographic information from both early responders and patients who did not receive an early response was
evaluated. Additionally, at week 14, it was evaluated if an early reaction might have anticipated the response, remission,
and more than little improvement.
Results: The logistic regression models were significant with a p-value of less than 0.001 and had a high accuracy of
78.2% in predicting remission. Compared to non-early responders, early responders had 3.2 times higher likelihood of
remission. Similar findings were seen for the answer, with an accuracy of 66.3% and a significance level of p<0.001.
Comparable results were seen for the GTMI outcomes, which demonstrated a high significance level of p<0.001 and an
accuracy of 74.4%. At 14 weeks, the early response group showed a 3.6 times greater reaction, whereas the GTMI was
4.9 times higher in the non-early responders.
Conclusion: The current study leads to the conclusion that higher treatment results at week 14 might be associated with
an early response. The current investigation shows that early response may be related to Dopamine reuptake inhibitors
and norepinephrine were provided in those who did not respond by week four, on the grounds that they would have
greater results.